Cylert - Pemoline

Pemoline (Cylert). Pemoline was introduced as an alternative stimulant. Its two key advantages are that it can be taken once a day, though with the extended-release versions of methylphenidate and Adderall this is less of an issue, and it may be less prone to abuse. It was generally believed that pemoline has a gradual onset of action, taking several weeks to reach full therapeutic benefit, but some researchers discount this assumption. 

As an aside, in March of 2005, Abbott Laboratories, the maker of Cylert , decided to take its drug off the U.S. market because of increasing concerns about it causing liver problems. Cylert had been available in the United States for 30 years for the treatment of ADHD and narcolepsy. However, the generic form of Cylert (pemoline) is still available. 

The primary drug therapies are psychostimulants which are indicated for both emotional based sleep disorders (i.e., narcolepsy) as well as ADHD. The drugs of choice are Ritalin (methylphenidate), dextroamphetamine or Cylert (pemoline), all CNS stimulants that effect the monoamine systems. The current therapies provide symptomatic relief but the current medications are not without side effects, including abuse potential, cardiovascular effects, insomnia, appetite suppression, head and stomach aches, crying and nervous mannerisms. 

Cycrin medroxyprogesterone, cyfluthrin [ban, bsi. iso] is a pyrethroid INSECTICIDE. Cylert pemoline. 

Cylert pemoline psychostimulant ADHD, autism, conduct disorder appetite reduction (very infrequent)... 

Pemoline pem -oh-leen Cylert ADHD Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement 37.5-112.5 mg/d PO... 

Methylphenidate (Ritalin), dextroamphetamine (Dexedrine), and pemoline (Cylert) are currently available in the United States. Methylphenidate has been the most widely used and is usually the first choice. Pemoline sometimes impairs liver function and is rarely used today due to the potential for toxicity. 

Pemoline is used for narcolepsy and for relieving drowsiness, as well as in treating attention-deficit disorder in children. Synonyms of this drug are tradon, deltamine, volital, phenoxazole, antimeran, cylert, and others. 

As of 2006, there are several branded medications approved for the treatment of ADHD however, there are only three chemicals that make up the primary active ingredients in these drugs the (5)-enantiomer of amphetamine (1), the 2(/ ),2 (7 )-enantiomer of methylphenidate (2), and the (/ )-enantiomer of atomoxetine (3). An older approved ADHD drug, pemoline (Cylert ), was withdrawn from the market in 2005 due to reported... 

The therapeutic indications for the psychomotor stimulants are quite limited. They are beneficial in the treatment of the hyperkinetic syndrome (attention deficit-hyperactivity disorder with minimal brain dysfunction). This is generally a childhood disease characterized by hyperactivity, inability to concentrate, and impulsive behavior. Amphetamines and the more extensively used methylphenidate paradoxically are quite effective in calming a large proportion of children with this disorder. Pemoline Cylert) is also used in the treatment of attention deficit disorder with hyperkinetic behavior. The mechanism by which these compounds are effective in this disorder is not known. 

The synthesis of 2-amino-4(5//)-oxazolones has been a very productive area of research since Traube and Ascher first prepared 2 nearly 90 years ago. Subsequently, literally hundreds of analogues have been prepared and evaluated, primarily as medicinal agents. For example, pemoline (Cylert ) 68 (Fig. 6.9), a central nervous system (CNS) stimulant relatively devoid of side affects has been... 

Page, J.G., Bernstein, J.E., Janicki, R.S., and Michelli, F.A. (1974) A multicenter trial of pemoline (cylert) in childhood hyperkinesis. In Conners, C.K., ed. Clinical Use of Stimulant Drugs in Children. The Hague, Netherlands Excerpta Medica, pp. 98-124. 

Pemoline (Cylert), (112.5 to 185.5 mg) was assessed in a 3-week open trial in 15 adolescents with CD, ADHD, and SUD (Riggs et ah, 1996). Three of the subjects were receiving other psychotropic medications (clonidine (Catapres) and paroxetine [Paxil]). All subjects had a significant improvement in ADHD symptoms (p <0.002) while 10/13 reported that the pemoline (Cylert) assisted in their substance rehabilitation. No subjects developed a significant elevation in their liver function tests, nor did any subjects test positive for substances of abuse for the duration of the study. No interactions between pemoline (Cylert) and any substances of abuse were reported. 

Another major safety concern in the treatment of youth with SUD is abuse of prescribed medications. Particular controversy has arisen around the use of stimulant medication in youth with SUD and ADHD. In one controlled study of adults, the use of methyl-phenidate (Ritalin) did not increase cocaine use or craving for cocaine (Grabowski et ah, 1997), suggesting that the abuse potential of stimulants may be overestimated. Riggs et al. (1996) did not report any difficulties with abuse when administering pemoline (Cylert) to a group of adolescents with SUD and ADHD. While Riggs and associates have observed that... 

More research has been done on pharmacotherapy of ADHD in children and adolescents with MR than for other disorders. Reviews by Aman (1996), Arnold et al. (1998), and Handen (1993) summarize the psychostimulant research (methylphenidate, amphetamine, and magnesium pemoline). Of the 10 or more group studies of methylphenidate or dextroamphetamine in children, adolescents, and adults with ADHD and MR/ DD since 1980, all but one were positive and statistically significant. They showed substantial benefit for motor overflow, attention span, and impulsiveness. Improvements were also seen in cognitive performance, some measures of social behavior, and independent play. The sole negative study was of adolescents and adults without ADHD, most of them with profound MR (see Aman, 1996). No studies of mixed amphetamine salts (Adderall) or magnesium pemoline (Cylert) were found for this population (Arnold et al., 1998). 

Pemoline is marketed in the United States under the prescription names Cylert and PemADD (56). It is available in immediate and sustained release formulas for the treatment of ADHD, but should not be considered as the first-choice therapy owing to its association with hepatic failure (57). Like methylphenidate, pemoline has not been well studied in sleep-deprived humans. 

Pemoline 37.5 mg once per day to 12 hr Low abuse potential Prescription Brand name Cylert ... 

Nasal 0.025, 0.05% sprays Ophthalmic 0.025% drops Pemoline (generic, Cylert)... 

In 1995, CHADD also had smaller grants from Abbott Laboratories ( 37,000) and Burroughs Wellcome ( 18,000). Abbott is the manufacturer of the stimulant pemoline (Cylert), used to treat ADHD. Burroughs Wellcome makes several medications used in pediatric medicine, including well-known antibiotics and cold medications. They also make the highly stimulating antidepressant Wellbutrin. 

Medication to treat ADHD should generally be used in concert with behavioral, psychological, and educational interventions and support for the child and family that is, medication alone is not recommended. Although some new nonstimulant medications are coming on the market for the treatment of ADHD, it will be some time until we know how well they work and with what side effects and risks. Meanwhile, the mainstay of medication treatment continues to be the stimulants, such as methylphenidate (trade name Ritalin), dextroamphetamine (trade name Dexedrine), and amphetamine/dextroamphetamine (trade name Ad-derall). The stimulant drug pemoline (trade name Cylert) is sometimes... 

Medications play an important part in the treatment of ADD. Stimulants are the mainstay of the treatment of ADD methylphenidate (Ritalin), dextroamphetamine (Dexedrine), and pemoline (Cylert). These differ in their half-lives, with Ritalin having the shortest and Cylert the longest. A warning has recently been issued about Cylert because of reports of sometimes fatal liver toxicity. Thus, it is recommended that it be used only if methylphenidate and dextroamphetamine are ineffective. There is individual variability in resporise, so that a person who does not respond to one may respond well to another. Other medications can also be effective in the treatment of ADD and may be useful, especially in residual ADD, where substance abuse may be an issue. These include tricyclic antidepressants (especially desipramine and imi-pramine) SSRIs, bupropion, venlafaxine, and clonidine. There are reports of antipsy-chotics and lithium being helpful in selected cases, as well. 

---